Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through cost and complexity reduction, has announced its participation in the 45th annual TD Cowen Health Care Conference. The company's management team is scheduled to present on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time.
Interested parties can access both live and archived versions of the presentation through the company's investor relations website at investors.outsetmedical.com. This presentation represents an opportunity for investors and stakeholders to gain insights into Outset Medical's innovative dialysis technology and business strategies.
Outset Medical (Nasdaq: OM) reported Q4 and full-year 2024 financial results, exceeding prior guidance. Q4 net revenue reached $29.5 million, with full-year revenue at $113.7 million. The company achieved significant gross margin improvements, reaching 36.5% in Q4 (37.7% non-GAAP), up 11 percentage points year-over-year.
The Tablo installed base grew 10% in 2024 to nearly 6,000 consoles. Recurring revenue from Tablo consumables and services increased 21% to $83.9 million for the full year. The company's net loss improved to $128 million ($2.46 per share) in 2024, compared to $172.8 million in 2023.
Following a January 2025 financing, Outset's cash position strengthened to approximately $210 million. The company provided 2025 revenue guidance of $115-125 million with expected non-GAAP gross margins in the high-30% range, projecting to use less than $50 million cash in 2025.
Outset Medical (Nasdaq: OM) announced that the FDA has confirmed all issues cited in their July 2023 Warning Letter have been successfully addressed. The medical technology company, which focuses on reducing dialysis cost and complexity through innovative technology, views this resolution as a significant milestone.
Chair and CEO Leslie Trigg emphasized the company's commitment to innovation and better dialysis outcomes, highlighting that product quality and regulatory compliance are fundamental to their success.
Outset Medical (Nasdaq: OM), a medical technology company focused on dialysis innovation, has scheduled its fourth quarter and full-year 2024 financial results announcement for Wednesday, February 19, 2025, after market close. The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day.
Chair and CEO Leslie Trigg and CFO Nabeel Ahmed will lead the discussion of financial and operating results. Interested participants can register online to receive dial-in details and a unique pin. A live and archived webcast will be available on the company's investor relations website.
Masimo (NASDAQ: MASI) has announced significant leadership changes effective February 12, 2025. Katie Szyman, currently worldwide president of Advanced Patient Monitoring at BD, has been appointed as the new CEO. Michelle Brennan, who served as Interim CEO, has been named Chairman of the Board, while Lead Independent Director Quentin Koffey becomes Vice Chairman.
Szyman brings over 35 years of experience, notably leading Edwards Lifesciences' Critical Care product group before its acquisition by BD in September 2024. Her appointment follows an extensive search process by Korn Ferry. The Board selected Szyman for her track record in accelerating revenue growth, experience in bringing new patient monitoring products to market, and success in leading industry talent.
The Board continues its previously announced strategic review of alternatives for both consumer audio and consumer healthcare businesses, with Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as legal advisor.
Outset Medical (Nasdaq: OM), a pioneering medical technology company focused on revolutionizing dialysis through cost and complexity reduction, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Chair & CEO Leslie Trigg will deliver a presentation on Wednesday, January 15, 2025, at 8:15 a.m. Pacific time.
Interested parties can access both live and archived versions of the presentation through the company's investor relations website at investors.outsetmedical.com.
Outset Medical (Nasdaq: OM) has announced a significant financial restructuring, including a $168.8 million private placement through the sale of Series A Non-Voting Convertible Preferred Stock at $200.00 per share. The company has also secured a new debt financing of up to $125 million maturing in 2030, which will be used to retire $200 million in prior debt.
The private placement was led by PFM Health Sciences, LP and Perceptive Advisors, with participation from T. Rowe Price Investment Management and other institutional investors. Additionally, board members and management will invest an extra $3.9 million upon shareholder approval.
The company reported unaudited Q4 2024 revenue of $29 million and full-year 2024 revenue of $113 million, exceeding previous guidance. Following the financing and debt repayment, Outset expects to have approximately $210 million in cash and equivalents with $100 million in debt.
Outset Medical (Nasdaq: OM), a medical technology company focused on revolutionizing dialysis through innovative technology, has announced its participation in the 2024 Stifel Healthcare Conference. The company's management team will deliver a presentation on Tuesday, November 19, 2024, at 10:20 a.m. Eastern time. Interested parties can access both the live presentation and archived recording through the 'Investors' section of Outset's website at investors.outsetmedical.com.
Outset Medical (Nasdaq: OM) presented new research at Kidney Week 2024 demonstrating significant benefits of their Tablo Hemodialysis System for home hemodialysis patients and caregivers. Two key findings were highlighted: First, patients reported improvements in depression and faster recovery from treatments, with high recommendation scores (NPS of 9.2-9.3). Second, caregivers showed strong confidence in supporting treatments, with 98% feeling confident and 100% satisfied with their role, resulting in high recommendation scores (NPS of 8.9). Additionally, a study in Kidney Medicine provided consensus recommendations for catheter use in home hemodialysis, suggesting individualized approaches for vascular access.
Outset Medical (Nasdaq: OM) announced it will release its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day, featuring Chair and CEO Leslie Trigg and CFO Nabeel Ahmed to discuss financial and operating results. Interested participants can register online to receive dial-in details and a unique pin. A live and archived webcast will be available on the company's investor relations website.